Our guideline working group has reviewed latest evidence and recommends therapeutic anticoagulation (instead of prophylactic) for mild and moderate COVID-19. This is based on review of latest evidence from 3 international trials, demonstrating marked benefit (net benefit in terms of organ-support free days, irrespective of D-dimer levels). No benefit (and possible harm) for severe COVID-19. Endorsed by MUHC P&T committee!
top of page
Search
Recent Posts
See AllThe ASP chairs are happy to publish the MUHC ASP annual report 2022-2023, now available in the Resources section of the MUHC ASP website....
00
The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus...
390
ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on...
190
bottom of page
Comments